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AbstractBloom syndrome (BS) is a rare, autosomal recessive genetic disorder characterized
by short stature, a skin rash associated with sun exposure, and an elevated likelihood of de-
veloping cancers of essentially all types, beginning at an early age. Cancer is the leading
cause of death for persons with BS, and its early onset results in a reported median lifespan
of <30 years. With fewer than 300 documented cases since BS was first described in 1954,
its rarity has challenged progress in advancing both the care of and the cure for persons with
BS. Presently, there are no known clinically actionable targets specific to persons with this
cancer predisposition syndrome, despite the fact that standard cancer treatments are often
contraindicated or must be substantially modified for persons with BS. Herein, Zachary
Rogers recounts his experience as a cancer patient with BS contemplating a substantially
customized chemotherapy regimen that highlights the need for development of individual-
ized treatments in the BS community. We also outline a patient-centered research and com-
munity action roadmap with the goal of improving and prolonging the lives of persons with
Bloom syndrome, including the facilitation of precision medicine development specific to
this condition.
INTRODUCTION
In 1954, David Bloom, a dermatologist in New York City, reported the cases of three children
with short stature and telangiectatic erythema, and noted that the cause was likely a genetic
syndrome (Bloom 1954). Bloom syndrome (BS) is now known to be an autosomal recessive
genetic disorder affecting the BLM gene, which codes for a DNA helicase protein in the
RECQ family (Cunniff et al. 2017). Since BS was first reported, approximately 300 cases
have been documented (Sanz et al. 2006). Since 1960, the Bloom’s Syndrome Registry4
(BSR) has existed to collect biological samples and natural histories of persons with BS. As
recently described in a review (Cunniff et al. 2017), BS is clinically variable and has primary
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features that include growth, dermatologic, and endocrine issues, along with a greatly in-
creased risk of cancer. From a molecular perspective, the BLM gene is one of the so-called
“guardians of the genome” because of its importance inmaintaining the structure and integ-
rity of DNA (Larsen and Hickson 2013); without the BLM protein, cells exhibit features of
chromosomal instability, leading to the greatly increased incidence of cancer seen in BS.
The molecular functions of BLM are many, including rescuing stalled forks and dissolving
double Holliday junctions; and BLM interacts with other DNA-repair proteins including
BRCA1, ATM, and RAD51. These functions and interactions are further described in
Cunniff et al. (2017).
As part of the 2017 Pediatric Cancer Nanocourse hosted by the Children’s Cancer
Therapy Development Institute5 in Beaverton, Orgeon, the authors (1) reviewed the BS liter-
ature, (2) discussed the state of the field with several current BS researchers and clinicians to
identify gaps in the current research, and (3) compiled a needs assessment to identify topics
of most importance to the community. We begin with excerpts from one patient’s story in his
own words.
ZACH’S STORY
Hi, my name is Zach Rogers and I have Bloom’s syndrome. I am 26 years old. I was born
weighing 3 lbs, 15 oz and was full-term. I was in distress in the womb and was born by
emergency C-section and taken by Life Flight to the local children’s hospital where I spent
3½ weeks.
I was originally diagnosed with IUGR [intrauterine growth restriction] and the doctors
tried to get me to “catch up.” I was placed on a feeding tube from age 2 months to 10
months. I began throwing up constantly and stopped eating by mouth. My parents decided
that for me to get better we should remove the feeding tube altogether. I was checked daily
for dehydration and reintroduced to eating foods. After a fewdaysmy appetite returned, and
I never threw up again for 4 years (when I had the stomach flu). It was a lesson to all my doc-
tors that I was being overfed and that I was not meant to “catch up.” I began to love food,
and to this day I love all foods except Fig Newtons.
Throughout my first 5 years of life I was followed closely in the neonatal program and reg-
ularlymetwith apsychologist, audiologist, ophthalmologist, cardiologist, gastroenterologist,
general pediatrician, and, of course, a geneticist. Although I saw a renowned geneticist,
because my condition was so rare, he did not diagnose me with Bloom’s syndrome. It
was not until I saw a dermatologist at age 2 years old for red raised bumps on my face (telan-
giectasia) that it was suggested that I might have Bloom’s syndrome. When the results came
back positive it was a new journey for myself, my parents and family, and my doctors.
My childhood was normal and happy. I had friends and was like any other child except I
was much smaller and needed to wear a hat and sunscreen in the summer time. I was able to
do everything that my friends could do, I was just shorter than them. I never felt bullied by
kids in my school. They were all very accepting and I had plenty of friends. I have always
had people in public stare at me, but I do not let it get to me. The only problem I had in
school and with friends is that the other kids liked to pick me up which I did not like. I got
into the habit of digging my fingernails into their hands as they picked me up and that
soon took care of that problem.
I had all my scheduled childhood immunizations in full doses with no side effects. I had
the usual colds and flus but no more often than other kids my age. I did get a lot of ear in-
fections and sinus infections as a child but had no serious illnesses.
5http://www.cc-tdi.org/ (accessed September 8, 2017).
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When I was 11 years old, I was at the pediatrician’s for a scout camp physical when a lump
was discovered on my neck. My pediatrician said I could go to camp (1 week) but we had to
watch it closely for changes and see a specialist immediately upon returning if the lymph
node was still swollen. I had some weight loss but otherwise felt fine and the lump was
not painful. After a CT scan it was determined that the lump was a harmless cyst but because
of my syndrome they would remove it as a precaution. The surgeon recognized it as cancer
as he was removing it, and I was soon diagnosed with large diffuse B cell non-Hodgkin’s lym-
phoma. Although we knewmy syndrome could cause cancer, it was unusual to get cancer at
such a young age.
At the time of my diagnosis I was working with an oncologist who was familiar with
Bloom’s syndrome, Dr. Charles Keller. I will always be thankful that Dr. Keller was living in
Utah at the time and knew enough about Bloom’s syndrome to know that a normal chemo-
therapy course would be detrimental to my health and that I would need a very personalized
treatment. I was treated under the CCGProtocol 5961 with the addition of rituximab and had
very reduced levels of chemotherapy to avoid toxicity because of DNA instability associated
with Bloom’s syndrome.
My chemotherapy was planned for about 50% of normal doses for my weight. However,
the levels were reduced even more and in the end my chemotherapy was personalized at
one-eighth to one-fourth of the normal levels for my weight. Radiation therapy was out of
the question because of my syndrome.
I underwent about 5 months of chemotherapy; in-patient for 1 week for chemotherapy,
then went home for 2 weeks and watched closely for infection, etc. I had a very good attitude
about my hospital visits and looked forward to ordering room service. I did lose all my hair
with the reduced doses but did not end up in the hospital with an infection. I did have a
severe reaction to the vincristine and was hospitalized for a weekend. About two-thirds
into my treatment my weight had dropped too low, and I had to have a feeding tube. This
was the hardest part of the treatment for me, and I remember feeling very angry about it.
My therapy was a work in progress and adjustments weremade as needed as wewent along.
After my treatment, I was followed with CT scans and watched closely. My lymphoma went
into remission, and I have been cancer-free now for 15 years.
After my cancer treatment, it was discovered through routine follow-up blood work that
my IgG levels were low. I was sent to an immunologist who ran more tests and discovered
that I had no immunities to my childhood vaccinations, and although he was concerned
about all my IgG levels, he was very concerned about my IgG2 level of 12. He gave me
the Prevnar vaccine then checkedmy immune response 2 weeks later. There was no immune
response. It was repeated twice with the same result. It was recommended that I receive IVIG
therapy on a regular basis. There were a lot of conflicting opinions in the Bloom’s syndrome
community regarding the benefits of IVIG, and we struggled with the decision. I rarely got
sick and there was no evidence, except on paper, that my immunities were low. My pedia-
trician concurred that I got sick less often than my siblings. It was assumed that my immuni-
ties had always been this low and were a symptom of the syndrome and not of the cancer
treatment.
Eventually the decision was made that it was not worth the risk of having IgG levels that
low, and I have received IVIG therapy (out-patient) in the hospital about every 8 weeks to
this day. The therapy makes me feel better overall. I sleep better, I am not as fatigued dur-
ing the day, and my allergies and stomach upset are improved. I can tell from my body
when it is time to have IVIG, and it is personalized to when I decide to come in, usually
about every 8–10 weeks. We have found that keeping the infusion slow reduces side effects
such as kidney/back pain, and the nurses that administer it follow a treatment plan that is
personalized for me that differs from the normal rate of flow for someone else my age or
weight.
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A few years after my cancer treatment there was an idea discussed among my doctors
that we think about trying monthly Lupron injections to increase my height since growth
hormones are not usually recommended for Bloom’s syndrome patients. The Lupron injec-
tions would delay and lengthen puberty to allow more time to grow until my growth plates
closed. I was told I was small even on the Bloom’s syndrome curve, and I was open to the
idea. We thought about it for a fewmonths. Mymom thought that my starting puberty might
have caused my lymphoma, so she liked the idea of suppressing my hormones as I went
through puberty as a protection against cancer. My doctors did not necessarily support
this theory, but it made sense to my mom, so she agreed. I had monthly Lupron injections
for about 5 years. My endocrinologist estimates that I gained about 4.5 in. in height by
this personalizedmedical treatment. If I would not have had the injections I wouldmost likely
be that much shorter than I am now. I am now 4′8′′. To my knowledge no other Bloom’s syn-
drome patient has tried this approach, but I did not have any negative effects and am happy
to be a little taller.
Today I am happy and healthy and got married a month ago. I have a good job, a beau-
tiful wife, and great doctors. I am living life to the fullest and trust that if I get cancer my doc-
tors know enough about my syndrome and past treatment to treat me with my own
personalized medicine. I have shared my cancer treatment protocol with others around
the world and am happy to help anyone that I can. I am very open about my syndrome
and treatments and feel like it is very important to share information within the Bloom’s syn-
drome community. We connect with others by attending conferences and on social media.
NEEDS AS IDENTIFIED BY FAMILIES AND PATIENTS AFFECTED
BY BLOOM SYNDROME
As Zach’s story highlighted, people with BS are faced with tremendous uncertainty about
how to choose appropriate medical treatments for cancer and other consequences of BS.
Important fundamental questions about the condition remain, and progress toward better
care and a potential cure has been challenging. Herein, we report a road map consisting
of three primary steps toward overcoming challenges to enable further progress.
Road Map Step 1: Establishing Protocols for Cancer Surveillance and Treatment
Persons with BS and their families need an appropriate screening and surveillance program
for cancer and to know how to treat cancers when they arise. In this area, two important ad-
vances have recently been made. First, the American Association of Cancer Researchers
(AACR) recently published cancer screening and surveillance recommendations for persons
with DNA repair disorders (Walsh et al. 2017). Second, building on this work, the director of
the BSR is authoring an article (with substantial contributions from an expert committee) that
will provide detailed health supervision guidelines primarily focused on cancer surveillance
and screening but also addressing other related health issues associated with BS (C Cunniff,
AR Djavid, S Carruba, et al., unpubl comm).
Dedicated efforts to track adherence to these surveillance protocols and their related
outcomes will enable us determine their efficacy. Our hope is to identify protocols that
will lead to lower mortality rates, as was seen in the Li–Fraumeni community when the
Toronto protocol was followed (Villani et al. 2016), as well as to identify and eliminate those
procedures that do not lead to better outcomes. Establishing standards and measuring ef-
fectiveness of protocols should also improve insurance reimbursement for this intensive pro-
cedure regimen.
Regarding the treatment of cancer in persons with BS once cancer has been diagnosed, a
small amount of information exists, but even fewer data have been gathered. As referenced
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in Zach’s story above, typical cancer treatment regimens should be modified for BS cancers.
Persons with BS are especially sensitive to DNA-damaging chemotherapy and radiation, and
the risk of secondary cancers or myelodysplasia must be considered. Specific (most often un-
successful) protocols have been published in isolated incidents (cf. Ma et al. 2001; Mizumoto
et al. 2013), and modified protocols and resultant outcomes are only shared sporadically
within the BS community. A vital step toward establishing treatment protocols is the collec-
tion of those that have been used previously and their outcomes. This information will help to
form a basic understanding of the interplay between the genomics and cancer treatment for
people with BS. Whereas this step will provide vital benefits by contributing to the develop-
ment of evidence-based customized cancer treatments, there is also hope that this informa-
tion will prove useful in the development of validated targets, as we discuss below. We
recommend that the data collection described above be done as part of the BSR
“Registry Data Project” described below.
Road Map Step 2: Building the Components of a Successful Rare Disease Community
The small number of persons with any given rare disease is a challenge for understanding
and curing the disease. However, recent advances in several areas (including communication
through social media, new incentives for rare disease drug development, better understand-
ing of rare diseases, and novel patient–researcher–industry relationships) lead us to believe
that there is an opportunity today to make significant strides in the understanding of BS.
We reviewed successes in other rare disease communities (such as cystic fibrosis, muscu-
lar dystrophy, and Fanconi anemia [FA], among others) and identified components that are
important for the BS community to develop and strengthen. Such components include a reg-
istry; a biorepository; strong, sustained patient participation; a collaborative research com-
munity; scientific leadership; disease models; a validated target; biopharma partners;
novel clinical trial designs; and funding. Below, for each of those components, we outline
the current state in the BS community and important goals to help strengthen our
community.
Bloom’s Syndrome Registry (BSR)
Since it was established in 1960, the BSR has operated intermittently, with limited funding
and periods of closed enrollment. In 2014, a new director was appointed and is now on
task to revitalize the organization. The BSR is integral to the research infrastructure needed
for the BS community. To better position the BSR for tackling research questions of relevance
to the community, we recommend initiation of a “Registry Data Project” with the following
immediate goals: update of the website and outreach campaign; appointment of a patient
advocacy advisory board; digitization of existing data, ensuring information management
and access; and a schedule for ongoing data collection.
Biorepository
The BSR previously collected biological samples of persons with BS (including tumor
samples), but little is known about the samples’ condition and thus their availability for
research. To our knowledge, tumor sequencing data (such as would facilitate the develop-
ment of precision oncological treatments) are not available for any of these samples. In con-
sultation with the advisory board, the BSR should reinstate and update this biorepository as
the sole source of biological samples related to BS. Immediate priority samples include
blood and fibroblast samples of registrants and tumor samples from registrants reporting
cancers.
Bloom syndrome: research and data priorities
C O L D S P R I N G H A R B O R
Molecular Case Studies
Campbell et al. 2018 Cold Spring Harb Mol Case Stud 4: a002816 5 of 11
 Cold Spring Harbor Laboratory Press on April 4, 2018 - Published by molecularcasestudies.cshlp.orgDownloaded from 
Strong Patient Participation
It is the authors’ assessment that families and persons with BS are cautiously willing to be
partners with the research community, but some have been discouraged in the past by
the lack of progress and information shared from the BSR and BS researchers. The dual re-
search–patient advocacy model used for the RecQ conferences in 2008 (Ellis et al. 2008)
and 2016,6 which we believe should continue, has helped build trust, but muchwork remains
to build closer ties. In order to better explain the new guidelines on health supervision in
plain language, and to encourage patient input back to clinicians and researchers, the au-
thors of this paper are developing a handbook for families and persons with BS. An annual
or biennial conference specifically focused on BS would further help build relationships with-
in the patient and family population and with researchers and clinicians.
Collaborative Research Community
We could not identify any researchers working on translational research specifically investi-
gating novel cancer treatments or curative treatments for BS. Individual oncologists of per-
sons with BS have shown interest in learning from others in the field, but as of yet there is no
“community of practice” for oncologists around treating BS cancers. As a community, we
need to raise awareness about BS and highlight the importance of our unanswered research
questions, not only for BS but also for cancer research and genetic research more generally.
We should seek to engage researchers working on other genomic instability syndromes
(e.g., FA, Li–Fraumeni, as well as the other RecQ disorders) to understand the potential
for applying their work to BS. As a community, we should recognize and promote those re-
searchers that have taken a leadership role and continue to raise awareness about BS to help
establish more attention from the funding agencies.
Disease Models
One challenge to better understanding BS is the lack of robust animal models that faithfully
reproduce the pathological processes and phenotypes seen in humans. Micewith loss of func-
tion ofMus (Blm analog in the housemouse) die in the embryonic phase; yet there does exist a
hypomorphicBlmmutationmouse thatmay be promising for preclinical research (Cunniff et al.
2017). Pigs are known to bemore analogous to humans inmanyways, especially for their use in
cancer research (Watson et al. 2016) but are more expensive to procure and maintain, and we
are unaware of any attempts to create a porcine model of BS or BS cancers. Zebrafish have
been noted for their suitability in studying DNA damage and repair (Pei and Strauss 2013),
and a zebrafishmodel for BS does exist yet lacks phenotype data (Cunniff et al 2017). Cell lines
for BS exist and are available from cell repositories, including the Coriell Institute for Medical
Research,7 but not all BS mutations recognized in the BSR are represented in these cell lines.
Although there were 64 different mutations noted in the BSR as of 2007 (German et al. 2007),
Coriell provides only 12 such mutations. As a community, we need to fully catalog disease
models available, continue to grow the pool of suitablemodels, and helpmake these available
to researchers. As the collection of BS tumors grows in our biorepository, research will also be
positioned to benefit from patient-derived xenografts (PDX), either in mice or zebrafish (Fior
et al. 2017) or other systems, to study cancers of BS and to develop treatments.
Validated Target
As of right now, we do not have a validated target for developing a therapy for BS nor for
precision treatment of BS cancers. Through a series of experiments throughout the 1970s,
6https://www.fredhutch.org/en/events/recq2016-partner-in-progress.html (accessed September 8, 2017).
7https://catalog.coriell.org/Search?q=%22BLM%22 (accessed September 8, 2017)
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1980s, and 1990s, the BLM gene was identified and was mapped to Chromosome 15
(Cunniff et al. 2017). Although much research continues, a complete understanding of the
role of the associated BLM protein and its interaction with other proteins is lacking. Many dif-
ferent mutations are known to be pathogenic (German et al. 2007), and different mutations
may have different “druggability” depending on the approach to treatment pursued (e.g., a
nonsense mutation may be amenable to exon skipping or readthrough, whereas other mu-
tations may require introduction of the functional gene). With respect to targets for cancer
treatment, we think the potential for the development of precision BS cancer treatments us-
ing a synthetic lethality concept is particularly enticing (O’Neil et al. 2017).
As part of the toolkit for developing validated targets for curing BS, several assays exist
for measuring Blm production. Standard techniques such as western blot analysis and immu-
nofluorescence are used in the literature. Some specific assays used for BS are the measure-
ment of the level of sister chromatid exchange (SCE) levels, which are elevated significantly
(∼10×) in BS cells (Chaganti et al. 1974). SCE levels have been shown to correlate with the
level of Blm expressed (Cunniff et al. 2017), and thus serve as a useful endpoint.
Clinical Trial Designs
The Food and Drug Administration (FDA) in the United States has shown a willingness to
work with patient communities in rare diseases, recognizing that those communities are
often themselves the “experts” and should weigh in on the tradeoffs on risk and uncertainty
that might be acceptable. The FDA has a designated Rare Diseases Program and has provid-
ed guidance on common issues in rare disease drug development.8 The European
Medicines Agency (EMA) has similarly showed an understanding of the challenges in rare
diseases, and the EU has funded research on small population clinical trials.9 As work pro-
gresses, our community will need to involve the FDA and the EMA early in discussing clinical
trial design. Natural histories collected as part of the BSR, as well as revitalizing the BSR on-
going data collection, will be vitally important to have.
Funding
There is almost no dedicated, sustained funding source for BS research. The BSR is support-
ed in part by a small grant, but needs additional funding. Each of the above components will
require funding, and our community will need to help identify additional sources of funding,
either through federal or foundation funding, or through capital campaigns by the BS
community.
RoadMap Step 3: Identifying ResearchQuestions of Most Interest to the BS Community
The above components of a robust rare disease community infrastructure must be realized in
order to address research questions and spur development of treatments or therapies. Our
needs assessment identified research questions around three major themes.
1. More effective, less toxic cancer treatments
• Precision Oncology in Bloom syndrome. Are there specific genetic mutations or other
signatures unique to BS tumors that would make these tumors more susceptible to
certain treatments, analogous to the poly(ADP) ribose polymerase (PARP) inhibitors
used for BRCA-mutated tumors (Lord and Ashworth 2016)? Are tumors in BS inherent-
ly more responsive to chemotherapy because of their reduced efficiency at DNA
8https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf
(accessed September 8, 2017).
9http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2017/02/event_detail_001393.jsp&mid=WC
0b01ac058004d5c3 (accessed September 8, 2017).
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repair, such as microsatellite instability (MSI)-high tumors seen in Lynch syndrome
(Kawakami et al. 2016)? Can an understanding of these features be tied back to
more strongly evidence-based BS cancer treatment protocols?
• Immuno-oncology. Unleashing the human immune system to fight cancers, either
through checkpoint inhibitors or by genetically engineering T cells (including CAR-
T) to better target cancer without the toxic side effects of chemotherapy or radiation
is being hailed as the fifth pillar of cancer care.10 Such treatment could be tremen-
dously important for BS cancer patients, who are more susceptible to secondary neo-
plasms resulting from chemo or radiation. However, the immune system is affected in
BS (Babbe et al. 2007), and it seems reasonable to suspect that genetic engineering
may face additional challenges in BS cells due to those cells’ impaired DNA repair
mechanisms. Would checkpoint inhibitors work in persons with BS? Can BS T cells
be reprogrammed to fight cancer? If so, can such reprogramming be done to not
only modify the T-cell receptors, but also to repair the BS gene in T cells to make these
cells behave more like healthy T cells?
2. Fundamental unknowns around Bloom syndrome clinical features
• Growth. The short stature observed in persons with BS is not fully understood. Growth
hormone production and secretion are normal (Diaz et al. 2006), yet growth hormone
treatment has shown to increase linear growth (Renes et al. 2013). What is the cause of
the short stature—a cell proliferation deficit, increased cell death, or something else?
Metabolic studies may be in order to answer these questions.
• Rash. There appears to be insufficient evidence as to whether the rash in BS (Giordano
et al. 2016) is actually caused by UV exposure, although persons with BS report the
onset or exacerbation of the rash with sun exposure, BS cells exposed to UV in vitro
do not show damage (Cunniff et al. 2017). A better animal model of BS may elucidate
this in more detail. Furthermore, there have been no reported recommended treat-
ments for the rash.
• Immunodeficiency. What is the cause (or mechanism) of immunodeficiency in BS, and
what is the interplay between this and immunotherapy for cancer treatment?
• Fertility. It has been reported that females with BS are subfertile andmales with BS are
infertile. However, up to date studies have not been performed that definitively
describe the cause behind this (for review, see Cunniff et al. 2017, which primarily
points to a study done in1987), and there is at least one report of a male with BS fa-
thering two children (Ben Salah et al. 2014). What is the mechanism by which BS caus-
es infertility? Is it possible that this varies by BLM mutation?
3. Restoring (or replacing) BLM in vivo
• Nonsense suppression. Mutations in BLM leading to BS can come in many forms
(German et al. 2007), but several of the mutations are nonsense mutations or prema-
ture termination codons (PTCs) in which the translation of the gene into protein is
stoppedmid-translation, leading to a nonfunctional protein. A therapeutic avenue be-
ing explored for other genetic conditions associated with PTCs is small molecule read-
through or nonsense suppression (Bordeira-Carriço et al. 2012; Lee and Dougherty
2012); this has been studied preclinically for many different conditions, including an-
other RecQ disorder, Werner syndrome (Agrelo et al. 2015). Advances in this area
10http://www.ascopost.com/issues/may-25-2016/how-immunotherapy-is-revolutionizing-cancer-care/ (posted May 25, 2016;
accessed September 8, 2017).
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have been limited by the most commonly used small molecules’ toxicity, but recently
it was discovered that the relevant active component of a common readthrough mol-
ecule, gentamicin, can be used at higher levels with minimal toxicity (Baradaran-
Heravi et al. 2017). Do existing readthrough compounds have any effect on BLM cells
containing PTCmutations? If so, is the nonsense suppression sufficient to restore BLM
and reduce SCEs to a therapeutic level? Interestingly, and related to the questions
around the BS rash, there have been reports of these readthrough molecules being
applied topically for other conditions that have nonsense mutation-associated rashes
(Kellermayer et al. 2006; Kuschal et al. 2013).
• Exon skipping. Another therapy being developed for other rare genetic disorders is
exon skipping, in which the mutated exon is “skipped over” by using an antisense ol-
igonucleotide.11 For BS mutations outside of the helicase domain, this may be worth
exploring. Would BS mutations be amenable to exon skipping?
• Compensation for BLM. The human body contains five RecQ helicases which are each
involved in various aspects of DNA replication and repair. In the absence of BLM, are
other RecQ helicases called to pitch in? It has been reported that RECQL5 may help
suppress SCEs when BLM function is impaired (Wang et al. 2003; Croteau et al. 2014).
If so, could it be up-regulated to compensate for the lack of BLM? It has been demon-
strated in cells that using RecG from Escherichia coli can reduce SCE levels (Killen et al.
2012)—is this translatable to a therapy?
• Gene therapy or gene editing. The development of CRISPR-type technology has rev-
olutionized the prospects for gene editing (Porteus 2016). Researchers have shown
the ability to correct the FA gene in patient-derived induced pluripotent cells
(Osborn et al. 2015), which is notable given FA is also a DNA repair-deficient disorder
and may have some of the challenges expected for gene editing in BS cells. Could a
similar approach be taken to correct the BLM gene in BS cells? If so, could ex vivo cor-
rection and reintroduction (minus traditional ablative preparation) of stem cells be a
viable approach to avoid leukemias in BS?
CONCLUSION
Other underserved patient populations are finding innovative academic, foundation, and in-
dustry arrangements to improve care and therapies for their communities (Ramseyet al. 2017)
and have shown the value of standard cancer screening and treatment protocols (Villani et al.
2016). Although we in the Bloom syndrome community face additional challenges given the
rarity of the condition, we are optimistic that by following the above roadmap, wemaymake
great strides in improving care for persons with BS and progressing toward a cure.
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